Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Hepatitis C virus | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | deoxyhypusine synthase | 0.007 | 0.6724 | 1 |
Loa Loa (eye worm) | deoxyhypusine synthase | 0.007 | 0.6724 | 0.5686 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0074 | 0.7743 | 0.3111 |
Leishmania major | p450 reductase, putative | 0.0084 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0074 | 0.7743 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0084 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0084 | 1 | 1 |
Echinococcus multilocularis | deoxyhypusine synthase | 0.007 | 0.6724 | 0.5686 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0084 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0084 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0084 | 1 | 1 |
Entamoeba histolytica | deoxyhypusine synthase, putative | 0.007 | 0.6724 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0084 | 1 | 1 |
Leishmania major | cytochrome P450 reductase, putative | 0.0074 | 0.7743 | 0.3111 |
Brugia malayi | deoxyhypusine synthase | 0.007 | 0.6724 | 0.5686 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0084 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0084 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0084 | 1 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0074 | 0.7743 | 0.3111 |
Entamoeba histolytica | deoxyhypusine synthase, putative | 0.007 | 0.6724 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0084 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0074 | 0.7743 | 1 |
Echinococcus granulosus | deoxyhypusine synthase | 0.007 | 0.6724 | 0.5686 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0052 | 0.2407 | 0.2407 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0084 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0084 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0084 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0084 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0084 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0084 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0084 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0084 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0052 | 0.2407 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0042 | 0.0151 | 0.0151 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0084 | 1 | 1 |
Schistosoma mansoni | deoxyhypusine synthase | 0.007 | 0.6724 | 0.6724 |
Loa Loa (eye worm) | hypothetical protein | 0.0084 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0084 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 261 nM | Inhibition of HCV RNA replication in Huh7 cells | ChEMBL. | 16451063 |
EC50 (functional) | = 261 nM | Inhibition of HCV RNA replication in Huh7 cells | ChEMBL. | 16451063 |
EC90 (functional) | = 4953 nM | Inhibition of HCV RNA replication in Huh7 cells | ChEMBL. | 16451063 |
EC90 (functional) | = 4953 nM | Inhibition of HCV RNA replication in Huh7 cells | ChEMBL. | 16451063 |
IC50 (binding) | = 20 nM | Inhibitory activity against HCV delta 21 NS5B RNA polymerase by SPA assay | ChEMBL. | 16451063 |
IC50 (binding) | = 20 nM | Inhibitory activity against HCV delta 21 NS5B RNA polymerase by SPA assay | ChEMBL. | 16451063 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.